These results are very preliminary but suggest a delay in the progression of islet-cell pancreatic cancer. Shares of Pfizer rose on the news. "These and previously reported phase 2 data contribute to the growing body of evidence indicating activity with sunitinib in patients with pancreatic islet cell tumors " said Dr. Mace Rothenberg recently of Pfizer (joined "the dark side" after a nice academic career in clinical oncology). I was his chaperone on tour around Grady Hospital when he came to visit. http://health.usnews.com/articles/health/healthday/2009/03/12/pancreatic...